Abstracts tagged "Psoriatic arthritis"

Abstract Number: 619 • 2017 ACR/ARHP Annual Meeting
Integrated Efficacy Analysis of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients with Active Psoriatic Arthritis
Peter Nash¹, Laura C Coates², Roy Fleischmann³, Kim Papp⁴, Juan J. Gomez-Reino⁵, Keith S Kanik⁶, Cunshan Wang⁶, Joseph Wu⁶, Thijs Hendrikx⁷ and William C Ports⁶, ¹Department of Medicine, University of Queensland, St Lucia, Brisbane, Australia, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ³Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ⁴Probity Medical Research and K. Papp Clinical Research Inc, Waterloo, ON, Canada, ⁵Fundacion Ramon Dominguez, Hospital Clinico Universitario, Santiago de Compostela, Spain, ⁶Pfizer Inc, Groton, CT, ⁷Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor under investigation for treatment of psoriatic arthritis (PsA). We examined tofacitinib efficacy in patients (pts) with active…
Abstract Number: 1829 • 2017 ACR/ARHP Annual Meeting
Patterns and Predictors of Progression of Sacroiliitis in Psoriatic Arthritis and Its Relationship with Human Leukocyte Antigen (HLA) Alleles. Results from the Toronto Cohort
Musaab Elmamoun¹, Justine (Yang) Ye², Richard J. Cook³, Vinod Chandran⁴ and Dafna D Gladman⁵, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, ⁴Medicine, Krembil Research Institute, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ⁵Rheumatology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) is clinically heterogeneous, with broad phenotypes of musculoskeletal (MSK) involvement including peripheral arthritis, enthesitis, dactylitis, and axial involvement. Sacroiliitis (SI) in…
Abstract Number: 620 • 2017 ACR/ARHP Annual Meeting
Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, up to 36 Months in Patients with Active Psoriatic Arthritis: Data from the Second Interim Analysis of OPAL Balance, an Open‑Label, Long-Term Extension Study
Peter Nash¹, Laura C Coates², Alan J. Kivitz³, Philip J Mease⁴, Dafna D Gladman⁵, Jose A Covarrubias-Cobos⁶, Dona Fleishaker⁷, Cunshan Wang⁷, Elizabeth Kudlacz⁷, Sujatha Menon⁷, Thijs Hendrikx⁸ and Keith S Kanik⁷, ¹Department of Medicine, University of Queensland, St Lucia, Brisbane, Australia, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ³Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, PA, ⁴Swedish Medical Center and University of Washington, Seattle, WA, ⁵Department of Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁶Unidad Reumatologica Las Americas S.C.P, Yucatán, Mexico, ⁷Pfizer Inc, Groton, CT, ⁸Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor under investigation for psoriatic arthritis (PsA). Interim data up to January 2017 (database not locked) report the…
Abstract Number: 1874 • 2017 ACR/ARHP Annual Meeting
Development of an Ultrasonographic Enthesitis Score for Psoriatic Arthritis Patients
Stephanie Tom^1,2, Yujie Zhong³, Richard J. Cook⁴, Sibel Z. Aydin^5,6, Gurjit S. Kaeley⁷ and Lihi Eder^8,9, ¹Women's College Hospital, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³MRC Biostatistics Unit, University of Cambridge, Cambridge, United Kingdom, ⁴Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, ⁵The Ottawa Hospital, Ottawa, ON, Canada, ⁶University of Ottawa, Ottawa, ON, Canada, ⁷University of Florida, Ponte Vedra Beach, FL, ⁸Women's College Research Institute, Women's College Hospital, Toronto, ON, Canada, ⁹Medicine, University of Toronto, Toronto, ON, Canada
Background/Purpose: Enthesitis affects approximately a third of patients with psoriatic arthritis (PsA) and is often considered the earliest site of inflammation. The accuracy of clinical…
Abstract Number: 623 • 2017 ACR/ARHP Annual Meeting
Tofacitinib Improves Composite Endpoint Measures of Disease in Patients with Psoriatic Arthritis
Philip S. Helliwell¹, Laura C Coates¹, Oliver FitzGerald², Peter Nash³, Enrique R Soriano⁴, M. Elaine Husni⁵, Ming-Ann Hsu⁶, Keith S Kanik⁶, Thijs Hendrikx⁷, Joseph Wu⁶ and Elizabeth Kudlacz⁶, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²ASRI, Dublin, Ireland, Dublin, Ireland, ³Department of Medicine, University of Queensland, St Lucia, Brisbane, Australia, ⁴Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁵Cleveland Clinic Lerner Research Institute, Cleveland, OH, ⁶Pfizer Inc, Groton, CT, ⁷Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor under investigation for the treatment of psoriatic arthritis (PsA). PsA is a heterogeneous disease and composite endpoints…
Abstract Number: 2030 • 2017 ACR/ARHP Annual Meeting
Patient Motivation in Inflammatory Arthritis: The Use of Ultrasound-Guided Patient Education to Endorse Medication Adherence and Facilitate Cost-Effective Targeted Management
Yasser M. El Miedany^1,2, Maha El Gaafary³, Nadia El Aroussy¹, Sally Youssef⁴ and Deborah Palmer⁵, ¹Rheumatology and Rehabilitation, Ain Shams University, Cairo, Egypt, ²Rheumatology, Darent Valley Hospital, Dartford, United Kingdom, ³Community, Environmental and Occupational Medicine, Ain Shams University, Abbassia, Egypt, ⁴Rheumatology & Rehabilitation, Ain Shams University, Cairo, Egypt, ⁵Rheumatology, North Middlesex University Hospital, London, United Kingdom
Background/Purpose: To assess the value of sharing the real-time ultrasound (US) images of the inflamed joints/ tendons with inflammatory arthritis patients and its impact on:…
Abstract Number: 179 • 2017 ACR/ARHP Annual Meeting
Mass Spectrometry Imaging of Synovium: A Novel Approach to Classify the Rheumatoid and Psoriatic Arthritis Patients
Beatriz Rocha^1,2, Berta Cillero-Pastor³, Gert Eijkel³, Lennart R. Huizing³, Cristina Ruiz-Romero^1,4, Andrea Cuervo^5,6, Ron M A Heeren³, Juan D. Cañete^5,6 and Francisco J Blanco^1,6, ¹Rheumatology Division, ProteoRed/ISCIII Proteomics Group, INIBIC - Hospital Universitario de A Coruña, A Coruña, Spain, A Coruña, Spain, ²The Maastricht Multimodal Molecular Imaging Institute (M4I), Division of Imaging Mass Spectrometry, Maastricht University, The Netherlands, Masstricht, Netherlands, ³The Maastricht Multimodal Molecular Imaging Institute (M4I), Division of Imaging Mass Spectrometry, Maastricht University, The Netherlands, Maastricht, Netherlands, ⁴CIBER-BBN Instituto de Salud Carlos III, INIBIC-CHUAC, A Coruña, Spain., A Coruña, Spain, ⁵Arthritis Unit, Rheumatology Department, Hospital Clinic, IDIBAPS, Barcelona, Spain, Barcelona, Spain, ⁶RIER-RED de Inflamación y Enfermedades Reumáticas, INIBIC-CHUAC, A Coruña, Spain, A Coruña, Spain
Background/Purpose: Psoriatic arthritis (PsA) and Rheumatoid arthritis (RA) are immune-mediated chronic inflammatory diseases. Synovial membrane is the initial site of inflammation in PsA and RA…
Abstract Number: 627 • 2017 ACR/ARHP Annual Meeting
Efficacy and Safety of Apremilast through 104 Weeks in Subjects with Moderate to Severe Psoriasis Randomized to Placebo, Apremilast, or Etanercept Who Continued on or Switched to Apremilast after Week 16 in a Phase 3b Study
Kristian Reich¹, Mark Goodfield², Lawrence Green³, Kristine Nograles⁴, Rongdean Chen⁴, Eugenia Levi⁴ and Richard G.B. Langley⁵, ¹Dermatologikum Hamburg, Hamburg, Germany, ²Leeds General Infirmary, Leeds, United Kingdom, ³George Washington University School of Medicine, Washington, DC, WA, ⁴Celgene Corporation, Summit, NJ, ⁵Dalhousie University, Halifax, NS, Canada
Background/Purpose: Many subjects (sbj) with chronic plaque psoriasis exhibit nail and scalp involvement that can markedly affect quality of life and be difficult to treat.…
Abstract Number: 2438 • 2017 ACR/ARHP Annual Meeting
Open Label Transitioning from Originator Etanercept to Biosimilar SB4 Compared to Continuing Treatment with Originator Etanercept in a Historical Cohort in Rheumatic Diseases in Daily Practice
L. Tweehuysen¹, V.J.B. Huiskes², B.J.F. Van den Bemt (PharmD, PhD)³, S. Teerenstra⁴, F.H.J. van den Hoogen⁵, C.H.M. van den Ende⁵ and A.A. Den Broeder⁵, ¹Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ²Pharmacy, Sint Maartenskliniek, Nijmegen, Netherlands, ³Pharmacy, Sint Maartenskliniek and Radboudumc, Nijmegen, Netherlands, ⁴Biostatistics, Radboudumc, Nijmegen, Netherlands, ⁵Rheumatology, Sint Maartenskliniek and Radboudumc, Nijmegen, Netherlands
Background/Purpose: Blinded transitioning from originator infliximab (INX) to biosimilar CT-P13 was not inferior to continuing INX treatment.1 Open label mandatory transitioning resulted in a slightly…
Abstract Number: 254 • 2017 ACR/ARHP Annual Meeting
Psoriatic Arthritis Sonographic Enthesitis Scores – Systematic Review of the Literature
Ofir Elalouf¹, Sibel Bakirci², Zahi Touma³, Melanie A Anderson⁴, Gurjit S. Kaeley⁵, Sibel Z. Aydin⁶ and Lihi Eder^7,8, ¹Rheumatology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ²Fellow in Rheumatology, Antalya, Turkey, ³Rheumatology, University of Toronto, Division of Rheumatology, Institute of Health Policy, Management and Evaluation, Toronto, ON, Canada, ⁴Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ⁵University of Florida, Ponte Vedra Beach, FL, ⁶University of Ottawa, Ottawa, ON, Canada, ⁷Medicine, University of Toronto, Toronto, ON, Canada, ⁸Women's College Research Institute, Women's College Hospital, Toronto, ON, Canada
Background/Purpose: Enthesitis is a prominent feature of spondyloarthropathy (SpA), including psoriatic arthritis (PsA). The evaluation of enthesitis has conventionally been conducted by clinical exam, a…
Abstract Number: 629 • 2017 ACR/ARHP Annual Meeting
Is Earlier Golimumab Treatment Initiation in Psa and As Patients Associated with Improved Outcomes?
Suneil Kapur¹, Proton Rahman², Michelle Teo³, Jodie Reis⁴, Rajwinder Dhillon⁵, Pauline Boulos⁶, Raman Rai⁷, Regan Arendse⁸, Julie Vaillancourt⁹, Emmanouil Rampakakis⁹, Allen J Lehman¹⁰, Francois Nantel¹¹ and Brendan Osborne¹¹, ¹University of Ottawa, 139 Greenbank Rd, Suite 203, ON, Canada, ²Rheumatology, St Claires Mercy Hospital, St Johns, NF, Canada, ³Balfour Medical Clinic, Penticton, BC, Canada, ⁴University of Saskatchewan, Saskatoon, SK, Canada, ⁵Private Practice, Niagara Falls, ON, Canada, ⁶Private Practice, Dundas, ON, Canada, ⁷Private Practice, Hamilton, ON, Canada, ⁸University of Saskatchewan, Saskatoon, ON, Canada, ⁹JSS Medical Research, Montreal, QC, Canada, ¹⁰Janssen Inc., Toronto, ON, Canada, ¹¹Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: Previous studies have suggested that treating patients earlier with biologics could improve disease outcomes. The aim of this analysis was to assess the impact…
Abstract Number: 2503 • 2017 ACR/ARHP Annual Meeting
Does Maastricht Ankylosing Spondylitis Enthesitis Scores Differ between Ankylosing Spondylitis, Psoriatic Arthritis and Rheumatoid Arthritis Patients?
Steffan Robstad Nilssen¹, Jintana B: Andersen¹, Hanne K. Vestaby¹, Glenn Haugeberg² and Brigitte Michelsen³, ¹Dept. of Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, ²Martina Hansens Hospital, Bærum, Norway, ³Dept. of Rheumatology, Hospital of Southern Norway Trust, kristiansand, Norway
Background/Purpose: The Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) is an enthesitis index developed and validated as an outcome measure in ankylosing spondylitis (AS), but is…
Abstract Number: 342 • 2017 ACR/ARHP Annual Meeting
Health Related Quality of Life Is Comparable in Psoriatic Arthritis and Rheumatoid Arthritis Patients in Spite of Different Disease Activity. SF-36 Data from a Large Prospective Observational Multicentre Study
Brigitte Michelsen^1,2, Till Uhlig¹, Eirik K Kristianslund¹, Joseph Sexton¹, Elisabeth Lie¹, Karen M Fagerli³, Hilde B Hammer⁴, Glenn Haugeberg^5,6 and Tore K Kvien⁷, ¹Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Dept. of Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, ³Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Dept of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁵Martina Hansens Hospital, Bærum, Norway, ⁶NTNU, Norwegian University of Science and Technology, Trondheim, Norway, ⁷Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: It is well established that RA patients have lower health related quality of life (HRQoL) across several domains compared with the general population, whereas…
Abstract Number: 631 • 2017 ACR/ARHP Annual Meeting
Predictors of Long-Term Retention of Methotrexate and Other Dmards with Golimumab in Rheumatoid Arthritis and Psoriatic Arthritis: An Analysis from a Prospective, Observational Registry
Derek Haaland¹, Anna Jaroszynska², B Haraoui³, Suneil Kapur⁴, Jacqueline Stewart⁵, Wojciech Olsynzynski⁶, Keltie Anderson⁷, Raman Rai⁸, Michael Starr⁹, Alexander Tsoukas¹⁰, Eliofotisti Psaradellis¹¹, Emmanouil Rampakakis¹¹, Cathy Tkaczyk¹², Allen J Lehman¹³, Francois Nantel¹² and Brendan Osborne¹², ¹Rheumatology, Clinical Immunology & Allergy, McMaster University, Barrie, ON, Canada, ²Private practice, Burlington, ON, Canada, ³Institut de Recherche en Rhumatologie de Montréal (IRRM), Montreal, QC, Canada, ⁴University of Ottawa, 139 Greenbank Rd, Suite 203, ON, Canada, ⁵Penticton Regional Hospital, Penticton, BC, Canada, ⁶University of Saskatchewan, Saskatoon, ON, Canada, ⁷University of Saskatchewan, Saskatoon, SK, Canada, ⁸Private Practice, Hamilton, ON, Canada, ⁹Rheumatology, McGill University, Pointe-Claire,, QC, Canada, ¹⁰McGill University, Montreal, QC, Canada, ¹¹JSS Medical Research, Montreal, QC, Canada, ¹²Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹³Janssen Inc., Toronto, ON, Canada
Background/Purpose: Previous studies have suggested that concomitant methotrexate therapy may increase the efficacy of biologic treatments. A scarcity of data exists on the benefits of…
Abstract Number: 2526 • 2017 ACR/ARHP Annual Meeting
Baseline Data from the Recent-Onset Psoriatic Arthritis Registry of the Spanish Society of Rheumatology
Rubén Queiro¹, Ana Laiz², Carlos Alberto Montilla-Morales³, Eva Galindez-Agirregoikoa⁴, Juan J. Bethencourt⁵ and Daniel Seoane⁶, ¹Rheumatology Department. Hospital Universitario Central de Asturias, Oviedo, Spain, ²Rheumatology, HU. Santa Creu i San Pau, Barcelona, Spain, ³Hospital Clínico Universitario de Salamanca, Salamanca, Spain, ⁴Rheumatology Division, Hospital Universitario de Basurto, Bilbao, Spain, ⁵Rheumatology, HU. Canarias, Sta. Cruz de Tenerife, Spain, ⁶Research Unit, Spanish Foundation of Rheumatology, Madrid, Spain
Background/Purpose: The natural history of psoriatic arthritis (PsA) is hardly known and the information regarding PsA prospective cohorts is very scarce worldwide. The information obtained…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.